Stock AnalizViridian Therapeutics, Inc.\DE VRDN
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Viridian Therapeutics, Inc.\DE (VRDN) is a healthcare company listed in the US with a market value of about $3.5B. In the twelve months to September 30, 2026 it had revenue of $26M and net income of -$454M, a net margin of -1724.1%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 132% a year, a 5-year average ROIC of -35%.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26M | $71M | $302000 | $314000 | $2M | $3M | $1M | $4M | $8M | $4M | $3M |
| Net income | -$454M | -$343M | -$270M | -$238M | -$130M | -$79M | -$111M | -$42M | -$33M | -$27M | -$17M |
| Free cash flow | -$343M | -$277M | -$233M | -$185M | -$95M | -$55M | -$30M | -$36M | -$27M | -$28M | -$15M |
| EPS (diluted) | $-4.38 | $-3.02 | — | $-5.31 | $-4.05 | $-6.66 | $-31.13 | $-20.04 | $-16.50 | $-20.70 | $-423.15 |
| Net margin | -1724.1% | -483.6% | -89387.1% | -75711.5% | -7329.2% | -2680.2% | -10544.3% | -938.6% | -390.0% | -662.3% | -496.8% |
| ROIC | — | -37.0% | -34.0% | -43.3% | -26.4% | -33.2% | -72.4% | -135.6% | -42.4% | -43.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $42.19, 37% above the current price; targets range from $33.00 to $54.00; the consensus rating is “Strong buy”; expected EPS is $-3.51 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Viridian Therapeutics, Inc.\DE pay a dividend?
Not currently.
Is Viridian Therapeutics, Inc.\DE a good stock to buy?
We do not give buy or sell advice. Viridian Therapeutics, Inc.\DE scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.